High Grade Glioma Clinical Trials in Miami, Florida

7 studies are recruiting for high grade glioma in Miami, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   University of Miami, Miami, Florida

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

2. Study of Olutasidenib and Temozolomide in HGG

   The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozol…

   Stage

   Phase 2

   Ages

   12 to 39

   Site

   University of Miami Hospital and Clinics, Miami, Florida

   Locations

   20 in total

   Run by

   Rigel Pharmaceuticals

   See if you can join NCT06161974 on ClinicalTrials.gov

3. PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

   This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a v…

   Stage

   Phase 2

   Ages

   3 to 39

   Site

   Nicklaus Children's Hospital, Miami, Florida

   Locations

   13 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05096481 on ClinicalTrials.gov

4. STARLITE for Unresectable High-Grade Gliomas

   The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-gra…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT06428045 on ClinicalTrials.gov

5. DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

   The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University of Miami Hospital, Miami, Florida

   Run by

   Ashish Shah

   See if you can join NCT06264388 on ClinicalTrials.gov

6. DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

   This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-F…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Locations

   5 in total

   Run by

   University of California, San Francisco

   See if you can join NCT06504381 on ClinicalTrials.gov

7. Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

   An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of…

   Stage

   Phase 1

   Ages

   Up to 18

   Site

   University of Miami Hospital, Miami, Florida

   Locations

   3 in total

   Run by

   Laminar Pharmaceuticals

   See if you can join NCT04299191 on ClinicalTrials.gov